Zobrazeno 1 - 10 of 25 pro vyhledávání: '"Snehangshu Kundu"'
1
Akademický článek
Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparibResearch in context
Autor: Xiaonan Zhang, Natallia Rameika, Lei Zhong, Verónica Rendo, Margus Veanes, Snehangshu Kundu, Sandro Nuciforo, Jordan Dupuis, Muhammad Al Azhar, Ioanna Tsiara, Pauline Seeburger, Shahed Al Nassralla, Viktor Ljungström, Richard Svensson, Ivaylo Stoimenov, Per Artursson, Markus H. Heim, Daniel Globisch, Tobias Sjöblom
Publikováno v: EBioMedicine, Vol 109, Iss , Pp 105368- (2024)
Summary: Background: Loss of heterozygosity (LOH) diminishes genetic diversity within cancer genomes. A tumour arising in an individual heterozygous for a functional and a loss-of-function (LoF) allele of a gene occasionally retain only the LoF allel
Externí odkaz: https://doaj.org/article/c93831231c574e67b595b2f52334f442
Zobrazit plný text záznamu
2
Akademický článek
Recurring EPHB1 mutations in human cancers alter receptor signalling and compartmentalisation of colorectal cancer cells
Autor: Snehangshu Kundu, Luís Nunes, Jeremy Adler, Lucy Mathot, Ivaylo Stoimenov, Tobias Sjöblom
Publikováno v: Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Background Ephrin (EPH) receptors have been implicated in tumorigenesis and metastasis, but the functional understanding of mutations observed in human cancers is limited. We previously demonstrated reduced cell compartmentalisation for soma
Externí odkaz: https://doaj.org/article/b87e40cc59cf4203a1ef3a43dd978c0d
Zobrazit plný text záznamu
3
Akademický článek
Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis
Autor: Snehangshu Kundu, Muhammad Akhtar Ali, Niklas Handin, Louis P. Conway, Veronica Rendo, Per Artursson, Liqun He, Daniel Globisch, Tobias Sjöblom
Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-19 (2021)
Abstract Background Genes in the Ras pathway have somatic mutations in at least 60 % of colorectal cancers. Despite activating the same pathway, the BRAF V600E mutation and the prevalent mutations in codon 12 and 13 of KRAS have all been linked to di
Externí odkaz: https://doaj.org/article/c6b41f70605140fe8ae77d5c5efb4251
Zobrazit plný text záznamu
4
Akademický článek
Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
Autor: Veronica Rendo, Snehangshu Kundu, Natallia Rameika, Viktor Ljungström, Richard Svensson, Kimmo Palin, Lauri Aaltonen, Ivaylo Stoimenov, Tobias Sjöblom
Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract Therapies targeting somatic bystander genetic events represent a new avenue for cancer treatment. We recently identified a subset of colorectal cancer (CRC) patients who are heterozygous for a wild-type and a low activity allele (NAT2*6) but
Externí odkaz: https://doaj.org/article/0075eeada5c6431e9aaae378bc12e7b8
Zobrazit plný text záznamu
5
Akademický článek
Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells
Autor: Snehangshu Kundu, Muhammad Akhtar Ali, Niklas Handin, Narendra Padhan, Jimmy Larsson, Maria Karoutsou, Kenneth Ban, Jacek R. Wiśniewski, Per Artursson, Liqun He, Mats Hellström, Tobias Sjöblom
Publikováno v: Genome Medicine, Vol 10, Iss 1, Pp 1-13 (2018)
Abstract Background The Ras pathway genes KRAS, BRAF, or ERBBs have somatic mutations in ~ 60% of human colorectal carcinomas. At present, it is unknown whether the remaining cases lack mutations activating the Ras pathway or whether they have acquir
Externí odkaz: https://doaj.org/article/e59e8395c9b944bfa4183f634a16c9e7
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje